A systematic analysis in efficacy and safety of nimotuzumab combined with chemoradiotherapy in treatment of advanced nasopharyngeal carcinoma

Liang X, Yang J, Gao T et al (2016) Nasopharynx cancer epidemiology in China. China J Cancer 25(11):835–840

Folprecht G, Lutz P, Schoffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Gastrointest Tumors 17(3):450–456

Scalvini L, Castelli R, La Monica S et al (2021) Fighting tertiary mutations in EGFR-driven lung-cancers: current advances and future perspectives in medicinal chemistry. Biochem Pharmacol 190:114643. https://doi.org/10.1016/j.bcp.2021.114643

Choo JR, Tan CS, Soo RA (2018) Treatment of EGFR T790M-positive non-small cell lung cancer. Target Oncol 13(2):141–156. https://doi.org/10.1007/s11523-018-0554-5

Liang R, Yang L, Zhu X (2021) Nimotuzumab, an anti-EGFR monoclonal antibody, in the treatment of nasopharyngeal carcinoma. Cancer Control 28:1073274821989301. https://doi.org/10.1177/1073274821989301

Vera DR, Eigner S, Henke KE et al (2012) Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nucl Med Biol 39(1):3–13

Crombet Ramos T, Mestre Fernández B, Mazorra Herrera Z et al (2020) Nimotuzumab for patients with inoperable cancer of the head and neck. Front Oncol 10:817. https://doi.org/10.3389/fonc.2020.00817

Liu C, Li M, Zhao G (2021) A systematic analysis in efficacy and safety of nimotuzumab combined with concurrent chemoradiotherapy in treatment of advanced esophageal cancer. J Clin Med Pract 25(5):10–15. https://doi.org/10.7619/jcmp.20201731

Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): New guidelines. Med Pediatr Oncol 37(1):1–3

Bates DW et al (1995) Evaluation of screening criteria for adverse events in medical patients. Med Care 33(5):452–462

Hu J, Gu W, He Z et al (2013) Observation of short-term curative effect of concurrent chemoradiotherapy combined with nimotuzumab in locally advanced nasopharyngeal carcinoma. Guangdong Med J (13):2094–2096. https://doi.org/10.13820/j.cnki.gdyx.2013.13.070

He S, Chen J, Zhang Y (2020) Clinical study of nimotuzumab combined with paclitaxel + cisplatin regimen concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Chin J Med 55(10):1102–1104. https://doi.org/10.3969/j.issn.1008-1070.2020.10.016

Li G, You Y, Gao J (2019) Observation of the recent efficacy of nituzumab combined with concurrent radiotherapy and chemotherapy for locally advanced NPC. J Med Theory Pract (01), 56–58. https://doi.org/10.19381/j.issn.1001-7585.2019.01.026.

Wu S, Wen Z, Wu X et al (2019) Observed the efficacy of nituzumab and concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer. Clin Med Eng 26:1701–1702

Zheng W, Qiu S, Xu Y et al (2014) Clinical curative effect analysis of radiotherapy, chemotherapy and nimotuzumab in the treatment of patients with locally advanced nasopharyngeal carcinoma. China Med Pharm 4(22):7–9

Chen Y, Quan F, Wang L (2016) Clinical effect of Nimotuzumab combined with Cisplatin concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. China Medical Herald 13:118–121

Lu H, Ni F, Liu L et al (2014) The recent efficacy of nituzumab combined with cisplatin concurrent chemoradiotherapy in advanced nasopharyngeal cancer. Tumor Pharm 2014:50–53

Yu H, Zhuang Y, Yu F et al (2014) The clinical study of nituzumab combined with cisplatin and three-dimensional conformal radiotherapy for the treatment of nasopharyngeal carcinoma. Guangxi Med 2014:882–884

Li D, Bai Y, Xie K et al (2015) Efficacy and safety of nimotuzumab combined with nedaplatin and three-dimensional conformal concurrent radiotherapy for nasopha-ryngeal cancer chemotherapy and the impact of TGF-β1, S100A8 and S100A9. J Med Res 44:136–139

Jia G (2017) Efficacy of nimotuzumab combined with conformal radiotherapy and chemotherapy in locally advanced nasopharyngeal carcinoma. Pract Clin Med. https://doi.org/10.13764/j.cnki.lcsy.2017.02.006

Mo Y, Yu H, Mo Z (2014) Efficacy observation of nimotuzumab combined with radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Chin J Clin 42(2):67–68. https://doi.org/10.3969/j.issn.1008-1089.2014.02.027

Zhang L, Huang Y, Hong S et al (2016) Gemcitabine plus cisplatin versus fluorourtourcil plus cisplatin in recurrence or metastatic nasopharyngeal carcinoma: a multicentre, randomized, open-label, phase 3 trial. Lancet 388(10054):1883–1892

Chen YP, Chan ATC, Le QT (2019) Nasopharyngeal carcinoma. Lancet 394(10192):64–80. https://doi.org/10.1016/S0140-6736(19)30956-0

Guan S, Wei J, Huang L, Wu L (2020) Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. Eur J Med Chem 207:112758. https://doi.org/10.1016/j.ejmech.2020.112758

Liu X, Wang P, Zhang C, Ma Z (2017) Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer. Oncotarget 8(30):50209–50220. https://doi.org/10.18632/oncotarget.16854

Rodriguez-Galindo C, Krailo MD, Krasin MJ et al (2021) Treatment of childhood nasopharyngeal carcinoma with induction chemotherapy and concurrent chemoradiotherapy. J Clin Oncol 39(14):1602

Yu Y, Guan H, Jiang L et al (2020) Nimotuzumab, an EGFR targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma. Int J Oncol 56(4):945–956. https://doi.org/10.3892/ijo.2020.4981

Xu Z, Shu H, Zhang F et al (2020) Nimotuzumab combined with irradiation enhances the inhibition to the HPV16 E6-promoted growth of cervical squamous cell carcinoma. Front Oncol 10:1327. https://doi.org/10.3389/fonc.2020.01327